Inari Medical, Inc. (NARI) is well-poised for growth, backed by a huge market opportunity for its products and its commitment to understanding the venous system. However, its dependency on the adoption of products is concerning.Shares of this currently Zacks Rank #3 (Hold) company have lost 32.4% in the past year against the industry’s 8.5% growth. The S&P 500 Index has risen 27.2% in the same time frame.NARI, with a market capitalization of $2.44 billion, is a commercial-stage medical device company. It se ...

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari's mission to improve pat ...

Inari Medical, Inc. (NARI) recently announced the positive two-year interim findings from the ClotTriever CLOUT registry. Principal investigator David Dexter, MD, FACS, a vascular surgeon at Sentara Vascular Specialists in Norfolk, VA, presented the research at the American Venous Forum meeting.Per the results, at two years, the rates of Post Thrombotic Syndrome (PTS) were outstanding and much lower than those found in previous Deep Vein Thrombosis (DVT) trials.Price PerformanceIn the past six months, NARI ...

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry. The data was presented at the American Venous Forum meeting by principal investigator, David Dexter, MD, FACS, a vascular surgeon at Sentara Vascular Specialists in Norfolk, Virginia. The interim results a ...

ATLANTA, March 01, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Inari Medical, Inc. ("Inari Medical" or the "Company") (NASDAQ:NARI) complied with federal securities laws. On February 28, 2024, Inari Medical disclosed that the Company had "received a civil investigative demand ("CID") from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the "Investigation"). The CID requests info ...

| --- | --- | --- | --- | --- | |-----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Inari Medical Investor Update February 2024 | | | | | | | | | | | This presentation and certain statements and information provided during this presentation may contain forward-looking statements. Allstatements other than statements of historical fact could be deemed forward-looking, including statements regard ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-K _________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________TO Commission File Number 001-39293 _______________ ...

Inari Medical, Inc. (NARI) is well-poised for growth, backed by a huge market opportunity for products and its commitment to understanding the venous system. However, its dependency on the adoption of products is concerning.Shares of this currently Zacks Rank #3 (Hold) company have lost 7.9% in the past year compared with the industry’s 0.7% decline. The S&P 500 Index has risen 20.8% in the same time frame.NARI, with a market capitalization of $3.31 billion, is a commercial-stage medical device company. It ...

Inari Medical (NARI) announced preliminary revenue results for fourth-quarter 2023. The preliminary results were almost in line with market expectations.Per the preliminary report, fourth-quarter 2023 net sales are estimated to be at least $132 million, suggesting a 22% rise from the year-ago reported figure. The Zacks Consensus Estimate of $131.8 million lies slightly below the preliminary figure.For 2023, NARI estimates revenues of $493.5 million, indicating a year-over-year increase of 24%. The Zacks Con ...

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance. Preliminary Fourth Quarter and Full Year 2023 Highlights Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be at least $132.0 million, up a ...